| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/100 - 1/500 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CHNRA6 |
| Entrez GeneID | 8973 |
| clone | 5B6G8 |
| WB Predicted band size | 57kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CHRNA6 (AA: 26-239) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CHRNA6抗体的3篇代表性文献示例(内容基于研究领域常见方向，供参考)：
---
1. **文献名称**：*Immunolocalization of the CHRNA6 nicotinic receptor subunit in the mouse brain*
**作者**：Gotti C. et al.
**摘要**：本研究利用特异性CHRNA6抗体，通过免疫组化技术揭示了CHRNA6蛋白在小鼠脑内多巴胺能神经元中的分布，尤其是在黑质和腹侧被盖区的显著表达，提示其与尼古丁成瘾及运动调节的潜在关联。
---
2. **文献名称**：*CHRNA6 antibody validation in Parkinson’s disease models*
**作者**：Quik M. et al.
**摘要**：作者通过Western blot和免疫荧光验证了CHRNA6抗体的特异性，并发现帕金森病模型中CHRNA6表达水平下降，表明该受体可能参与疾病相关的多巴胺能神经元退行性变机制。
---
3. **文献名称**：*Association of CHRNA6 polymorphisms with nicotine dependence: Evidence from antibody-based protein quantification*
**作者**：Liu Y. et al.
**摘要**：研究结合基因分型和CHRNA6抗体检测，发现特定基因变异可导致外周血单核细胞中CHRNA6蛋白表达差异，为尼古丁依赖的分子机制提供了新证据。
---
**注**：以上文献为示例，实际文献需通过PubMed、Google Scholar等平台检索关键词“CHRNA6 antibody”结合研究主题(如神经疾病、成瘾机制)获取。
The CHRNA6 antibody targets the α6 subunit of the nicotinic acetylcholine receptor (nAChR), encoded by the *CHRNA6* gene. This subunit forms ligand-gated ion channels involved in neurotransmission, particularly in dopaminergic pathways. CHRNA6 is predominantly expressed in the central nervous system, including regions like the ventral tegmental area and substantia nigra, where it modulates dopamine release. Its role in regulating reward and addiction mechanisms links it to neurological and psychiatric disorders, such as Parkinson’s disease, nicotine dependence, and substance abuse.
CHRNA6 antibodies are essential tools for studying the protein's expression, localization, and function. They enable detection via techniques like Western blotting, immunohistochemistry, or immunofluorescence, aiding research into nAChR-related signaling pathways. These antibodies also help explore genetic variants of *CHRNA6* associated with disease susceptibility or behavioral traits. For instance, studies use them to investigate how α6 subunit dysfunction impacts dopamine signaling or addiction vulnerability.
Commercially available CHRNA6 antibodies are typically raised in hosts like rabbits or mice, often validated for specificity against recombinant or native proteins. Researchers must confirm cross-reactivity and optimal experimental conditions, as nAChR subunits share structural homology. Proper validation ensures reliability in distinguishing CHRNA6 from related subunits (e.g., α4 or β2), critical for accurate mechanistic insights. Overall, CHRNA6 antibodies are pivotal in advancing neuropharmacology and addiction research.
×
